Difference between revisions of "Dactinomycin (Cosmegen)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Uterine cancer" to "Endometrial cancer") |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Endometrial cancer]] | ||
*[[Ewing's sarcoma]] | *[[Ewing's sarcoma]] | ||
*[[Gestational trophoblastic neoplasia]] | *[[Gestational trophoblastic neoplasia]] | ||
*[[Osteosarcoma]] | *[[Osteosarcoma]] | ||
*[[Soft tissue sarcoma|Rhabdomyosarcoma]] | *[[Soft tissue sarcoma|Rhabdomyosarcoma]] | ||
| − | *[[ | + | *[[Wilms' tumor]] |
==Patient drug information== | ==Patient drug information== | ||
| Line 21: | Line 22: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Generic names:''' AC-DE, | + | *'''Generic names:''' AC-DE, actinomycin D |
*'''Brand names:''' Cosmegen, Dacmozen, Lyovac | *'''Brand names:''' Cosmegen, Dacmozen, Lyovac | ||
| Line 33: | Line 34: | ||
[[Category:DNA synthesis inhibitors]] | [[Category:DNA synthesis inhibitors]] | ||
| − | [[Category: | + | [[Category:Endometrial cancer medications]] |
[[Category:Ewing's sarcoma medications]] | [[Category:Ewing's sarcoma medications]] | ||
[[Category:Gestational trophoblastic neoplasia medications]] | [[Category:Gestational trophoblastic neoplasia medications]] | ||
| + | [[Category:Osteosarcoma medications]] | ||
[[Category:Soft tissue sarcoma medications]] | [[Category:Soft tissue sarcoma medications]] | ||
| − | [[Category: | + | [[Category:Wilms' tumor medications]] |
[[Category:FDA approved in 1964]] | [[Category:FDA approved in 1964]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 03:08, 25 November 2018
General information
Class/mechanism: Antibiotic oncologic, intercalates between guanine and cytosine DNA base pairs, inhibiting DNA and RNA synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Endometrial cancer
- Ewing's sarcoma
- Gestational trophoblastic neoplasia
- Osteosarcoma
- Rhabdomyosarcoma
- Wilms' tumor
Patient drug information
- Dactinomycin (Cosmegen) patient drug information (Chemocare)[3]
- Dactinomycin (Cosmegen) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/10/1964: Initial FDA approval
Also known as
- Generic names: AC-DE, actinomycin D
- Brand names: Cosmegen, Dacmozen, Lyovac
References
Categories:
- Drugs
- Intravenous medications
- Vesicant chemotherapy
- DNA synthesis inhibitors
- Endometrial cancer medications
- Ewing's sarcoma medications
- Gestational trophoblastic neoplasia medications
- Osteosarcoma medications
- Soft tissue sarcoma medications
- Wilms' tumor medications
- FDA approved in 1964
- WHO Essential Cancer Medicine